Skip to main content
TipRanks
Go Ultimate75% OFF

ABIONYX Pharma SA (ABNX) AI Stock Analysis

7 Followers
FR:ABNX

ABIONYX Pharma SA

(Paris:ABNX)

Select Model
Rating:42Neutral
Price Target:EUR 1.50â–¼(-4.46% Downside)
Action:upgraded
Date:09/18/26

The overall score is very low, driven primarily by severe financial distress including declining revenue, negative margins, and a weakening balance sheet. Technical trends confirm persistent bearish momentum, and the negative P/E ratio underscores the lack of profitability. The company's high cash burn and need for future financing present significant risks.

Positive Factors
ApoA-I/HDL therapeutic platformA focused platform around apoA-I and HDL biology gives ABIONYX a defined scientific identity and supports development across severe inflammatory and infectious conditions. If clinical development succeeds, the lead approach could provide a reusable foundation for advancing related biologic candidates.
Negative Factors
Severe operating lossesOperating losses remain extremely large relative to revenue, showing that the current business model has not yet reached an economically sustainable scale. Without materially higher revenue or a substantial reduction in expenses, continued losses can consume capital and limit the resources available for pipeline development.

ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)

-80%-60%-40%-20%0%20%FR:ABNX-61.59%EWQ-1.35%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 67.95M
Dividend Yield
―
Average Volume (3M)
140.26K
Price to Earnings (P/E)
-7.0
Beta (1Y)
-0.17
Revenue Growth
-10.38%
EPS Growth
-72.05%
Country
France
Employees
49
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ABIONYX Pharma SA Business Overview & Revenue Model

Company Description

ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This...

How the Company Makes Money

ABIONYX Pharma SA primarily aims to generate revenue through the development and eventual commercialization (directly or via partners) of its drug candidates; however, specific, current revenue streams and amounts (e.g., product sales, licensing inco...

ABIONYX Pharma SA Financial Statement Overview

Summary

Financial health is weak. Revenue is declining, gross margin is critically low at 9.3%, and operating and net losses are widening. The balance sheet shows a sharp drop in equity and rising debt-to-equity to 0.89. While cash burn has modestly improved, the company continues to consume cash and will likely need additional funding.

Income Statement

12Very Negative

Balance Sheet

18Very Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.88M4.06M4.60M4.64M5.25M675.00K
Gross Profit209.00K376.00K844.00K618.00K636.00K259.00K
EBITDA-5.85M-5.70M-5.27M-4.53M-4.01M-7.42M
Net Income-8.06M-5.55M-4.40M-3.52M-4.21M-5.82M
Balance Sheet
Total Assets36.54M12.86M13.45M14.83M15.82M21.83M
Cash, Cash Equivalents and Short-Term Investments26.87M3.52M3.23M4.10M4.05M7.93M
Total Debt15.18M3.81M3.10M3.39M4.01M4.96M
Total Liabilities20.86M8.60M6.03M6.91M8.65M11.15M
Stockholders Equity15.68M4.26M7.42M7.92M7.17M10.68M
Cash Flow
Free Cash Flow-3.41M-3.17M-3.60M-3.83M-3.53M-6.86M
Operating Cash Flow-3.28M-2.93M-3.60M-3.70M-3.36M-6.69M
Investing Cash Flow-94.00K-205.00K-100.00K-130.00K-175.00K1.34M
Financing Cash Flow26.87M3.42M2.80M3.89M-194.00K3.97M

ABIONYX Pharma SA Technical Analysis

Technical Analysis SentimentNegative
Last Price1.57

Price Trends

50DMA1.65Negative
100DMA1.79Negative
200DMA2.48Negative

Market Momentum

MACD-0.01Positive
RSI44.34Neutral
STOCH28.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Negative. The current price of 1.57 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 1.65, and below the 200-day MA of 2.48, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 28.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABNX.

ABIONYX Pharma SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ABNX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ABNXFR:ABNX42NeutralEUR 67.95M-7.02-80.82%―-10.38%-72.05%
FR:ALSENFR:ALSEN41NeutralEUR 80.64M-1.83-54.15%――6.26%
FR:SIGHTFR:SIGHT40UnderperformEUR 18.61M-1.0452.39%―-610.31%43.88%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%FR:ABNXFR:ALCOXFR:SIGHTFR:ALSENDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ABNX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ABNXABIONYX Pharma SA1.57-2.55-61.90%
FR:ALCOXNicox SA0.28-0.02-8.33%
FR:SIGHTGenSight Biologics0.08-0.03-27.62%
FR:ALSENSensorion SAS7.62-8.68-53.23%

ABIONYX Pharma SA Corporate Events

ABIONYX Pharma Reports October Share and Voting Rights Data

Nov 6, 2026

ABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and intensive care, developing apoA-I-based biotherapies and HDL vectors for immune-inflammatory disorders. Its pipeline addresses serious conditions with limited treatme...

ABIONYX Pharma Partners With CHU de Lille on CER-001 Sepsis Research

Nov 4, 2026

ABIONYX Pharma has signed a strategic partnership with CHU de Lille’s Burn Treatment Center and Intensive Care–Resuscitation Department to study apoA-I, functional HDL, endotoxin burden and immune-inflammatory dysregulation in severely burned and cri...

ABIONYX Pharma Secures Full CER-001 Manufacturing Chain with AXPLORA Partnership

Oct 27, 2026

ABIONYX Pharma has completed an end-to-end manufacturing chain for its flagship biopharmaceutical CER-001 by signing a strategic purification partnership with CDMO AXPLORA, adding to existing industrial agreements with TEXCELL and OLON. The collabora...

ABIONYX Taps OLON for Scalable Manufacturing of Complex Biologic CER-001

Oct 7, 2026

ABIONYX Pharma has entered a strategic manufacturing partnership with global CDMO OLON to advance CER-001, a complex biologic based on full-length recombinant human apoA-I assembled into biomimetic HDL particles. The deal positions OLON to handle ups...

ABIONYX Pharma Updates Voting Rights as It Advances Sepsis-Focused Biotherapies

Oct 2, 2026

ABIONYX Pharma, a biopharmaceutical company focused on sepsis and critical care, develops apoA-I-based biologics and HDL carriers to address immune-inflammatory dysregulation in severe diseases where effective treatments are lacking. Backed by strong...

ABIONYX Pharma trims bond debt with share-backed repayment, keeps cash runway to 2028

Oct 2, 2026

ABIONYX Pharma has partially repaid €1.75 million of its bond financing with Fenja Capital II A/S, settling about 70% in cash and 30% through a reserved capital increase of €0.52 million via the issuance of 331,299 new shares. The new shares, priced...

ABIONYX bolsters cash to €26.9m as losses deepen and sepsis strategy advances

Sep 23, 2026

ABIONYX Pharma reported first-half 2026 consolidated revenue of €1.9 million, generated entirely by its IRIS Pharma ophthalmology CRO unit, while its sepsis and LCAT deficiency programs remain pre-revenue and continue to supply bioproducts for Norum...

ABIONYX Pharma Taps TEXCELL to Advance Viral Safety and Industrialization of CER-001

Sep 10, 2026

ABIONYX Pharma has entered a strategic partnership with TEXCELL, a division of ABL Diagnostics, to conduct viral safety and clearance studies for CER-001 as it prepares validation batches of its bioproduction process in France. The work is central to...

ABIONYX Pharma Updates Share Capital and Voting Rights Structure

Sep 7, 2026

ABIONYX Pharma reported that as of August 31, 2026, its outstanding share capital stood at 43,736,415 shares, corresponding to 55,932,492 gross voting rights and 55,705,013 net voting rights. The disclosure, made in line with AMF regulations on votin...

ABIONYX Pharma Posts €1.9 Million H1 Revenue and Extends Cash Runway to 2028

Aug 27, 2026

ABIONYX Pharma reported consolidated half-year revenue of €1.9 million at the end of June 2026, entirely driven by its ophthalmology CRO unit IRIS Pharma, with biotech operations recording no sales as the company continues supplying its bioproduct fr...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026